Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors

AIDS

Volumn 17, Issue 6, 2003, Pages 791-799

  Gonzales, Matthew J ^a   Wu, Thomas D ^b   Taylor, Jonathan ^c   Belitskaya, Ilana ^c   Kantor, Rami ^a   Israelski, Dennis ^a   Chou, Sunwen ^d   Zolopa, Andrew R ^a   Fessel, W Jeffrey ^e   Shafer, Robert W ^a,f  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GENENTECH INC   (United States)

^c STANFORD UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e AIDS Research   (United States)

^f NONE   (United States)

Author keywords

Antiretroviral therapy; HIV diagnostic tests; HIV drug resistance; Resistance mutations; Reverse transcriptase inhibitors

Indexed keywords

ABACAVIR; ADEFOVIR; DIDANOSINE; LAMIVUDINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CHI SQUARE DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; GENE CLUSTER; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; TREATMENT OUTCOME; UNINDEXED SEQUENCE; VIRUS ISOLATION;

BASE SEQUENCE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LOGISTIC MODELS; MOLECULAR SEQUENCE DATA; MUTATION; PRINCIPAL COMPONENT ANALYSIS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0038640538     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200304110-00003     Document Type: Article

References (26)

1. Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000, 283:2417-2426.
2. British HIV Association. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001, 2:276-313.
3. EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001, 15:309-320.
4. US Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection A. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 5 February, 2002. http://www.hivatis.org/trtgdlns.html
5. Parikh U, Hammond J, Calef C, Larder B, Schinazi RF, Mellors JW. Mutations in retroviral genes associated with drug resistance. In Human Retroviruses and AIDS: a Compilation and Analysis of Nucleic and Amino Acid Sequences. Edited by Kuiken CL, Foley B, Hahn BH, Korber, F. McCutchan, P. A. Marx, et al. Los Alamos: Los Alamos National Laboratory; 2001.
6. Shafer RW, Stevenson D, Chan B. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucl Acids Res 1999, 27:348-352.
7. Kuiken CL, Foley B, Hahn BH, Korber, F. McCutchan, P. A. Marx, et al. Human Retroviruses and AIDS: a Compilation and Analysis of Nucleic and Amino Acid Sequences. Los Alamos: Los Alamos National Laboratory; 1999.
8. Gonzales MJ, Machekano RN, Shafer RW. Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a Northern California clinic-based population. J Infect Dis 2001, 184:998-1006.
9. Felsenstein J. PHYLIP (phylogeny inference package) version 3.5. Seattle: University of Washington; 1993.
10. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol 1995, 57:289-300.
11. Mellors JW, Bazmi HZ, Schinazi RF, Roy BM, Hsiou Y, Arnold E, et al. Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob Agents Chemother 1995, 39:1087-1092.
12. Poch O, Sauvaget I, Delarue M, Tordo N. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J 1989, 8:3867-3874.
13. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256:1783-1790.
14. Shafer RW, Kozal MJ, Winters MA, Iversen AK, Katzenstein DA, Ragni MV, et al. Combination therapy with zidovudine and didanosine selects for drug- resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis 1994, 169:722-729.
15. Shirasaka T, Kavlick MF, Ueno T, Gao WY, Kojima E, Alcaide ML, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995, 92:2398-2402.
16. Boucher CA, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992, 165:105-110.
17. Hanna GJ, Johnson VA, Kuritzkes DR, Richman DR, Leigh Brown AJ, Savara AV, et al. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis 2000, 181:904-911.
18. Yahi N, Tamalet C, Tourres C, Tivoli N, Fantini J. Mutation L210W of HIV-1 Reverse Transcriptase in Patients Receiving Combination Therapy. incidence, association with other mutations, and effects on the structure of mutated reverse transcriptase. J Biomed Sci 2000, 7:507-513.
19. Miller MD, Margot NA, Lu B. Effect of baseline nucleoside-associated resistance on response to tenofovir DF (TDF) therapy: Integrated analyses of studies 902 and 907. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [abstract 43].
20. Boyer PL, Hughes SH. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1995, 39:1624-1628.
21. Back NK, Berkhout B. Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1997, 41:2484-2491.
22. Larder BA. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J Gen Virol 1994, 75:951-957.
23. Byrnes VW, Emini EA, Schleif WA, et al. Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors. Antimicrob Agents Chemother 1994, 38:1404-1407.
24. Kleim JP, Rosner M, Winkler I, et al. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV- 1 replication results in the emergence of nucleoside RT-inhibitor- specific (RT Leu-74→Val or Ile and Val-75→Leu or Ile) HIV-1 mutants. Proc Natl Acad Sci USA 1996, 93:34-38.
25. Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein DA, et al. HIV-1 genotypic resistance patterns predict response to saquinavir- ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med 1999, 131:813-821.
26. Shulman NS, Zolopa AR, Passaro DJ, Murlidharan U, Israelski DM, Brosgart CL, et al. Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. J Acquir Immune Defic Syndr 2000, 23:221-226.